Articles tagged with Colon Cancer
Researchers at the University of California San Diego School of Medicine have found that high cannabis use is associated with increased mortality in colon cancer patients. The study analyzed data from over 1,000 patients and found a significant link between heavy cannabis use and reduced survival rates.
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
A 20-year initiative that offered flexible screening options at a major health system doubled screening rates and cut cancer incidence by a third, halving deaths. The program eliminated racial disparities in outcomes, with Black patients' deaths declining from 52.2 to 23.5 per 100,000.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
A UConn clinical trial confirms walnuts improve colonic health by reducing systemic inflammation and increasing the production of potent anti-inflammatory molecules called urolithins. Elevated urolithin A levels correlated with reduced colon cancer risk, particularly in obese patients.
Researchers analyzed CRC tumors with high tumor mutation burden to characterize BRAF-associated mutations and decipher their role in carcinogenesis. They found TMB-high tumors likely arise from a heterogeneous population of cells harboring numerous gene mutations distinct from driver oncogenes.
A new study suggests that CT scans could account for 5% of all cancer cases each year, primarily due to radiation exposure. The largest risk is among infants, followed by children and adolescents. To mitigate this risk, reducing the number of scans and doses per scan can help save lives.
The study directly compared Droplet-based scRNA (D-scRNA) and Picowell-based scRNA (P-scRNA) platforms for analyzing human mucosal biopsies. D-scRNA provides more detailed insights, but requires resources and may introduce contamination. P-scRNA is gentler, more resource-efficient, but less effective in capturing rare cell types.
A survey by the Annenberg Public Policy Center found that over half of Americans believe drinking alcohol increases their chances of developing cancer. The Surgeon General's advisory on alcohol and cancer risk also contributed to increased public awareness, with nearly 3 in 10 respondents saying they would be less likely to accept a dr...
A new study led by the University of Michigan Rogel Cancer Center found that patients with three specific variants face no extra risk of dying from their cancer. The researchers used data from the Surveillance, Epidemiology and End Results programs in Georgia and California, looking at a total of about 78,000 patients with breast, colo...
A new clinical guideline from the American Gastroenterological Association suggests that artificial intelligence-assisted colonoscopy may improve polyp detection rates, but its impact on preventing colorectal cancer remains uncertain. The guideline recommends a cautious approach to widespread adoption, emphasizing the need for further ...
Researchers at the University of Texas at El Paso have developed a portable, blood-based device that can detect colon cancer using a biomarker called CCSP-2. The device has the potential to provide early detection and treatment options for this second-deadliest US cancer, making it a significant advancement in colorectal cancer screening.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
The updated recommendations from the US Multi-Society Task Force on Colorectal Cancer aim to achieve a benchmark of 90% exams with adequate bowel preparation. The guidelines focus on optimizing bowel preparation before, during, and after colonoscopy, including patient education, dietary restrictions, and choice of preparation agent.
A recent study published in CANCER suggests that higher levels of physical activity may lessen and even eliminate survival disparities among colon cancer survivors. Cancer survivors who regularly exercised achieved better subsequent survival rates than those seen in the matched general population, with a 3.1% lower risk at year three.
Deep Nanometry enables high-speed analysis of nanoparticles, detecting even trace amounts of rare particles like extracellular vesicles indicative of colon cancer. This technique has potential applications in various fields including vaccine development and environmental monitoring.
Researchers discover that the gene HMGA1 'opens' regions of the genome to activate stem cell genes, leading to tumor development and progression. High levels of HMGA1 also allow mutant tumor cells to escape detection by immune cells.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.
A blood test detecting circulating tumor DNA (ctDNA) can predict stage 3 colon cancer patients' risk of recurrence. Adding anti-inflammatory drug celecoxib to post-surgery treatment improves disease-free survival for those with positive ctDNA tests.
A blood test using Signatera detected tiny fragments of tumor DNA in the blood, which showed that adding celecoxib to treatment may improve disease-free survival for patients with stage III colon cancer. The analysis found significantly improved outcomes for those taking celecoxib compared to placebo.
A review of 3,000 studies suggests microplastics in the air may cause serious health problems, including colon cancer, poor lung function, and infertility. The tiny plastic particles are believed to contribute to chronic pulmonary inflammation, increasing the risk of lung cancer.
Researchers at UW-Madison found two microbial bile acids that affect colon cancer risk in opposite ways, with one slowing growth and the other fueling tumors. The study provides a roadmap for new cancer detection methods and treatments.
A new study suggests that a person's biological age can predict their risk of developing colon polyps and early colorectal cancer. Accelerated aging, which is higher than chronological age, may be linked to a greater risk of developing the disease, highlighting the importance of early screening.
A study led by UF Health Cancer Center researchers found that a toxin in the bacteria Campylobacter jejuni accelerates the spread of colorectal tumors. The findings could lead to new tools for detecting metastatic colorectal cancer early, ultimately helping determine patients who need more aggressive treatments.
The American College of Surgeons' annual cancer report reveals that breast, bladder, and pancreatic cancers are increasingly treated with personalized therapies before surgery. Cancer stage at diagnosis remains a significant factor in determining patient survival rates.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Scientists are investigating whether resveratrol, a compound found in red grapes, can prevent bowel cancer. The COLO-PREVENT trial is testing multiple potential prevention drugs, including aspirin and metformin, to see if they can slow down tumour growth and reduce the risk of bowel cancer.
Researchers found higher levels of CD47 expression linked to more aggressive tumors, immune cells, and oncogenic signaling. Targeting CD47 could lead to improved outcomes with immunotherapy drugs, especially in cases where existing treatments are ineffective.
Researchers have found that specific E. coli bacteria in the gut promote colon cancer by binding to intestinal cells and releasing a DNA-damaging toxin called colibactin. This binding is made possible by bacterial pili and adhesins, which can be targeted to prevent tumor development.
Researchers at Tel Aviv University have discovered a new cancer mechanism that prevents the immune system from attacking tumors. The discovery was made by reversing this mechanism, which stimulates the immune system to fight cancer cells, including those resistant to prevailing forms of immunotherapy.
Researchers create genetic barcoding approach to record cellular events and clonality in vivo, revealing that colorectal cancer originates from multiple healthy cells. This work provides a new understanding of the transition from polyclonal to monoclonal composition in advanced stages.
Researchers found a link between non-functional p53 genes and the regenerative cell state in ulcerative colitis, leading to cancer progression. A new diagnostic test could identify aberrant cells earlier using molecular tools.
A Kaiser Permanente study found that close to 39% of adults aged 45-49 returned their FIT kit, compared to nearly 38% of adults aged 50. The study suggests that adults in this age group have a similar colorectal cancer risk as those aged 50.
Younger adults diagnosed with colorectal cancer have later-stage disease with more aggressive types of tumors. Obesity, family history, inflammatory bowel disease, and symptoms are strongly associated factors. These findings highlight disparities in colon cancer incidence among younger adults, particularly non-Hispanic Black patients.
A new study found that 5-fluorouracil kills cells by interfering with RNA synthesis, not DNA damage. The findings suggest that combining 5-FU with drugs affecting RNA synthesis could make it more effective in patients with gastrointestinal cancers.
Scientists at RIKEN CPR created a method to change albumin's molecular ID card, allowing for targeted treatments against diseases like cancer. The new technology can transport proteins out of the body, mimicking drug delivery and removal.
A new study aims to increase follow-up care for patients who receive abnormal stool-based fecal immunochemical tests, focusing on improving coordination between primary and specialty clinics. The goal is to improve colorectal cancer screening processes in underserved populations, increasing survival and reducing mortality.
The Affordable Care Act has led to increased guideline-concordant care for non-white patients, rural residents, and those from the most deprived neighborhoods in Pennsylvania. This improvement is associated with better cancer outcomes, including survival rates.
Researchers have discovered a new class of natural antimicrobials called microcins that can target specific strains of bacteria causing cholera, inflammatory bowel disease, and colon cancer. Microcins are highly selective and can potentially remove unwanted bacteria without disrupting the human gut microbiome.
A University of Oklahoma researcher has been awarded a NIH grant to evaluate thousands of natural products with therapeutic potential. The goal is to identify specific components of these products that have anticancer properties and understand how they work.
A new Cleveland Clinic study reveals that diet-derived molecules called metabolites are the main drivers of young-onset colorectal cancer risk, particularly those associated with red and processed meat. The research suggests that addressing diet with doctors can help prevent colon cancer in younger adults.
A new AI algorithm assesses immune cells in early-stage bowel cancer tumours to predict recurrence risk. The CD3 Score test has been shown to reliably identify high-risk cancers that are more likely to recur within five years of surgery, enabling clinicians to make informed decisions about chemotherapy treatment.
A study identifies a 10-gene biomarker that can predict whether stage II or III colon cancer patients will benefit from adjuvant chemotherapy. The gene signature also has the potential to predict which patients may respond to immunotherapy.
A new study published in JAMA Network Open shows that an at-home fecal immunochemical testing (FIT) screen can reduce the risk of colorectal cancer death by 33%, comparable to screening colonoscopy. FIT is a non-invasive test that involves mailing a stool sample to the laboratory for analysis.
A clinical trial found that fecal microbiota transplants can boost the effectiveness of immunotherapy in a range of gastrointestinal cancers. The study identified specific bacterial strains associated with better or worse responses, and showed promise for improving treatment outcomes.
Researchers found that eliminating racial disparities in follow-up colonoscopy rates and quality would significantly reduce colorectal cancer incidence and mortality. By closing these gaps, the study aims to achieve health equity and find innovative solutions for true change.
Researchers found that regorafenib synergizes with TAS102 to inhibit cancer growth, angiogenesis, and microvessel density in preclinical models of colorectal and gastric cancers. The combination also suppresses ERK1/2 activation regardless of KRAS or BRAF mutational status.
A new study has identified specific RNAs that may help identify stage II colon cancer patients who are likely to benefit from chemotherapy following surgery. The researchers found that certain housekeeping RNAs were up-regulated in patients with recurrence, suggesting their potential role in the metastatic process.
Researchers at Weill Cornell Medicine have identified cellular and molecular markers that can predict when pancreatic cancer will spread to the liver or other organs. The study found that patients with early-stage pancreatic cancer who showed signs of immune exhaustion were more likely to develop liver metastases.
The article reviews recent advances in applying artificial intelligence to oncology, showcasing promising improvements in cancer care. The authors emphasize the need for interdisciplinary collaboration, rigorous validation, and ethical principles to harness AI's potential.
Researchers at NTNU have developed a way to reconstruct 3D models of the colon using single images taken by capsule endoscopy cameras. These models can aid in detecting abnormalities and signs of disease, enabling specialists to make diagnoses faster.
A study by Nanyang Technological University found that eight in 10 gastroenterologists in the Asia-Pacific region accept and trust AI-powered tools for diagnosing colorectal polyps. The study also highlights the need for more research into what influences doctors' acceptance of AI in their medical practice.
A subset of patients with stage 3 colon cancer who have PIK3CA mutations may benefit from celecoxib treatment, which improved overall survival and reduced disease-free survival rates. The study's findings suggest a potential personalized approach to additional therapy for patients with early-stage colon cancer.
Researchers at Northwestern University discovered an attenuated virus that can help eliminate cancer in mice and prevent future tumor development. The therapy works by raising 'red flags' on tumors to alert immune cells to attack them.
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
Researchers found that only 41.5% of cancer patients could successfully book a new appointment at a clinic due to various barriers, including language issues and workflow challenges.
Researchers created nanomicelles containing substances already approved for human use, which reduced inflammation in the tumor microenvironment and facilitated the action of the immune system. The treatment induced a reduction of over five times in tumor volume compared to untreated tumors.
A short course of immunotherapy prior to surgery was highly effective in treating colon cancer, with 95% of patients showing significant tumor reduction or complete elimination. The treatment also showed promising results in preventing cancer recurrence and metastasis over a two-year follow-up period.
A quality improvement analysis found that many US residents live within 30 miles of a clinical trial site, highlighting disparities in access. The study highlights concerns about equity and fairness in healthcare resource distribution, particularly for marginalized communities.